BioGenex to Introduce miRNA-ISH System for Tumor Diagnosis

BioGenex is scheduled to introduce its miRNA system, along with the Xmatrx automation platforms, at the United States and Canadian Academy of Pathology annual meeting in Seattle next week, the devicemaker announced.

The system integrates detection kits, more than 200 miRNA probes, improved protocols for visualizing formalin-fixed paraffin-embedded tissues and automation platforms, according to the company.

"miRNA in situ visualization offers the opportunity to potentially reduce cancer death by 10% over the next decade by accurate tumor characterization," said Krishan Kalra, founder and CEO of BioGenex. — Anisa Jibrell